Medicare Rebates: Bigger is Better, But is Big Government Best?
This article was originally published in RPM Report
An inspector General report takes the first public look at rebating under Medicare Par D.For Henry Waxman the message is that private negotiation isn't working to capture deep enough discounts. But the more important message for sponsors is that the report shows CMS remains firmly committed to the private sector drug insurance model.
You may also be interested in...
When it comes to Medicare Part D, the brand counts at least that’s what some of the biggest plans have concluded. From Humana/Walmart to CVS/Member Health, the drug benefit is increasingly a story of branding, both in the selling proposition to consumers and in the branding of certain plans as underperformers by CMS
At present, the federal government is prohibited from negotiating outpatient prescription drug prices with pharmaceutical companies on behalf of Medicare Part D. But, Senator Barack Obama (and perhaps John McCain, whose stance on this policy is unclear) favors a health system in which the government can bring its bargaining power to the table. What happens when the other shoe drops?
Big Pharma companies say its too early to tell what prices will look like under Medicare Part D next year. That is in part because they can't be sure yet what prices they will get in 2006. That won't be clear until claims are reconciled this fall.